Tvardi's TTI-101 breast cancer trial posts results after early termination
Tvardi Therapeutics posted results for its terminated Phase 1b/2 TTI-101 combination study in HR+/HER2- metastatic breast cancer.
- The Phase 1b/2 "REVERT-Breast Cancer" trial (NCT05384119) tested the STAT3 inhibitor TTI-101 added to palbociclib or ribociclib plus an aromatase inhibitor or fulvestrant in metastatic HR-positive, HER2-negative breast cancer. The study was terminated prior to Phase 2 due to slow accrual.1 Enrollment reached 6 participants (actual).1 The trial began January 9, 2023 and reached primary and study completion on May 6, 2024, with results first posted September 24, 2026. Tvardi Therapeutics is the lead sponsor, with the National Cancer Institute as a collaborator.
Fact check notes
- Checker's noteThe phrase 'closed early last year' is inaccurate: the study's primary/study completion date was 2024-05-06, which does not align with 'last year' relative to the results-posting date of 2026-09-24 (a roughly two-year gap, not one year).
- Sentence removed
Tvardi Therapeutics had one item post this week, tied to a study that closed early last year.
contradicted: Study completion was in 2024, not 'last year' relative to the results posting date of Sept 2026; this timing claim is inaccurate.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.